Browse studies

Find your next paid study

1,260 recruiting studies matching your filters

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cispl…

Locally Advanced Cervical AdenocarcinomaLocally Advanced Cervical Adenosquamous CarcinomaLocally Advanced Cervical Squamous Cell Carcinoma+5 more

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07061977

Phase 1

A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given …

Locally Advanced or Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07730021

Phase 2

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors t…

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more

Studies on Thyroid Nodules and Thyroid Cancer

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to furth…

Hurthle Cell Thyroid CancerTall Cell Variant Thyroid CancerFollicular Thyroid Cancer+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001160

NLM Scrubber: NLM's Software Application to De-identify Clinical Text Documents

Background: Electronic health records contain a vast amount of data about diseases and treatments. Researchers could use this data to test their ideas, but the…

Personally Identifiable Information

Estimated

~$10 – $1,125

Actual pay is set by the research site.

National Library of Medicine (NLM)NCT02795806

Phase 4

PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial

This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection o…

Hernia Abdominal WallBotox InjectionHernia Incisional Ventral+4 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

The Cleveland ClinicNCT07220382

Phase 1

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refra…

B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Vironexis Biotherapeutics Inc.

Phase 2

A Phase 2 Study of SMARCA4/2 Inhibitor (FHD-286) for POU2F3-Positive Small-Cell Lung Cancer

This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing smal…

Small Cell Lung Cancer

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07551635

An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform aph…

Solid Tumor, AdultColorectal CancerNon Small Cell Lung Cancer+14 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

A2 Biotherapeutics Inc.NCT04981119

Phase 2

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) a…

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

Estimated

~$75 – $2,800

Actual pay is set by the research site.

CatalYm GmbHNCT07246863

Phase 3

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. …

Non-small Cell Lung Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07554339

Phase 1

An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Background: Cancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and qualit…

Intractable PainPalliative Care

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Institute of Neurological Disorders and Stroke (NINDS)NCT02522611